| [177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ... The Lancet 397 (10276), 797-804, 2021 | 702 | 2021 |
| Tailoring adjuvant endocrine therapy for premenopausal breast cancer PA Francis, O Pagani, GF Fleming, BA Walley, M Colleoni, I Láng, ... New England Journal of Medicine 379 (2), 122-137, 2018 | 672 | 2018 |
| Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer BIG 1-98 Collaborative Group New England Journal of Medicine 361 (8), 766-776, 2009 | 654 | 2009 |
| Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical … MM Regan, P Neven, A Giobbie-Hurder, A Goldhirsch, B Ejlertsen, ... The lancet oncology 12 (12), 1101-1108, 2011 | 470 | 2011 |
| Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International … G Viale, A Giobbie-Hurder, MM Regan, AS Coates, MG Mastropasqua, ... Journal of clinical oncology 26 (34), 5569-5575, 2008 | 412 | 2008 |
| Controversies around epithelial–mesenchymal plasticity in cancer metastasis ED Williams, D Gao, A Redfern, EW Thompson Nature Reviews Cancer 19 (12), 716-732, 2019 | 402 | 2019 |
| Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial M Rabaglio, Z Sun, KN Price, M Castiglione-Gertsch, H Hawle, ... Annals of oncology 20 (9), 1489-1498, 2009 | 193 | 2009 |
| Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib KM Giles, FC Kalinowski, PA Candy, MR Epis, PM Zhang, AD Redfern, ... Molecular cancer therapeutics 12 (11), 2541-2558, 2013 | 174 | 2013 |
| Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/HER2-negative breast cancer—the evaluating treatment with … L Gianni, M Mansutti, A Anton, L Calvo, G Bisagni, B Bermejo, ... JAMA oncology 4 (3), 302-308, 2018 | 153 | 2018 |
| RNA-induced silencing complex (RISC) Proteins PACT, TRBP, and Dicer are SRA binding nuclear receptor coregulators AD Redfern, SM Colley, DJ Beveridge, N Ikeda, MR Epis, X Li, CE Foulds, ... Proceedings of the national academy of sciences 110 (16), 6536-6541, 2013 | 151 | 2013 |
| SLIRP, a small SRA binding protein, is a nuclear receptor corepressor EC Hatchell, SM Colley, DJ Beveridge, MR Epis, LM Stuart, KM Giles, ... Molecular cell 22 (5), 657-668, 2006 | 151 | 2006 |
| PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu] Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP … JP Buteau, AJ Martin, L Emmett, A Iravani, S Sandhu, AM Joshua, ... The Lancet Oncology 23 (11), 1389-1397, 2022 | 131 | 2022 |
| Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer C Duffy, A Sorolla, E Wang, E Golden, E Woodward, K Davern, D Ho, ... NPJ precision oncology 4 (1), 24, 2020 | 125 | 2020 |
| Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial M Colleoni, W Luo, P Karlsson, J Chirgwin, S Aebi, G Jerusalem, P Neven, ... The lancet oncology 19 (1), 127-138, 2018 | 116 | 2018 |
| Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics A Sorolla, E Wang, E Golden, C Duffy, ST Henriques, AD Redfern, ... Oncogene 39 (6), 1167-1184, 2020 | 90 | 2020 |
| TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group.[177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic … MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ... Lancet 397 (10276), 797-804, 2021 | 89 | 2021 |
| Clinical implications of circulating tumor cells of breast cancer patients: role of epithelial–mesenchymal plasticity LM McInnes, N Jacobson, A Redfern, A Dowling, EW Thompson, ... Frontiers in oncology 5, 42, 2015 | 72 | 2015 |
| Notch-induced transcription factors are predictive of survival and 5-fluorouracil response in colorectal cancer patients PA Candy, MR Phillips, AD Redfern, SM Colley, JA Davidson, LM Stuart, ... British journal of cancer 109 (4), 1023-1030, 2013 | 72 | 2013 |
| Activation of canonical BMP4-SMAD7 signaling suppresses breast cancer metastasis BL Eckhardt, Y Cao, AD Redfern, LH Chi, AD Burrows, S Roslan, ... Cancer research 80 (6), 1304-1315, 2020 | 53 | 2020 |
| Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study … J Gligorov, B Ataseven, M Verrill, M De Laurentiis, KH Jung, HA Azim, ... European Journal of Cancer 82, 237-246, 2017 | 53 | 2017 |
Erik ThompsonFaculty of Health, School of Biomedical Sciences, Queensland University of TechnologyVerified email at qut.edu.au
